Alan H. Auerbach - Founder, Chief Executive Officer & President @ Puma Biotechnology - Crunchbase Person Profile
Should You Buy Puma Biotechnology Inc (PBYI) Stock After it Has Gained 6.09% in a Week?
Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology
Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug - TheStreet
PharmaShots - Incisive news in 3 shots on Twitter: "Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer https://t.co/KKTvnp68jJ https://t.co/LR02TGd4oT" / Twitter
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
Pfizer Announces Agreement with Puma Biotechnology and Lyrica Success - Clinical Professionals
Why Puma Biotechnology's Shares Jumped 20% on Monday | The Motley Fool
Puma Biotechnology - Crunchbase Company Profile & Funding
Accord entre Pierre Fabre et Puma Biotechnology
PUMA BIOTECHNOLOGY, INC. : Precio Acción Bourse | PBYI | US74587V1070 | MarketScreener
Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in China - Los Angeles Business Journal
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
The Prognosis For Puma Biotechnology (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma Biotechnology
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
Medical Affairs eLearning - MSL Society
Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Resumen: Puma Biotechnology y Pierre Fabre firman acuerdo de licencia exclusiva para desarrollar y comercializar NERLYNX® (neratinib) en Europa | Business Wire
